|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huxley RR, Ansary-Moghaddam A, Clifton P,
Czernichow S, Parr CL and Woodward M: The impact of dietary and
lifestyle risk factors on risk of colorectal cancer: A quantitative
overview of the epidemiological evidence. Int J Cancer.
125:171–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong
QH, Wang L and Wang JP: The prognostic role of BRAF mutation in
metastatic colorectal cancer receiving anti-EGFR monoclonal
antibodies: A meta-analysis. PLoS One. 8:e659952013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kolligs FT, Bommer G and Göke B:
Wnt/beta-catenin/tcf signaling: A critical pathway in
gastrointestinal tumorigenesis. Digestion. 66:131–144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lei S, Dubeykovskiy A, Chakladar A,
Wojtukiewicz L and Wang TC: The murine gastrin promoter is
synergistically activated by transforming growth factor-beta/Smad
and Wnt signaling pathways. J Biol Chem. 279:42492–42502. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo RJ, Huang E, Ezaki T, Patel N,
Sinclair K, Wu J, Klein P, Suh ER and Lynch JP: Cdx1 inhibits human
colon cancer cell proliferation by reducing beta-catenin/T-cell
factor transcriptional activity. J Biol Chem. 279:36865–36875.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ripple MJ, Parker Struckhoff A,
Trillo-Tinoco J, Li L, Margolin DA, McGoey R and Del Valle L:
Activation of c-Myc and Cyclin D1 by JCV T-Antigen and β-catenin in
colon cancer. PLoS One. 9:e1062572014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lian J, Tang J, Shi H, Li H, Zhen T, Xie
W, Zhang F, Yang Y and Han A: Positive feedback loop of
hepatoma-derived growth factor and β-catenin promotes
carcinogenesis of colorectal cancer. Oncotarget. 6:29357–29374.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang R, Sun Q, Wang P, Liu M, Xiong S, Luo
J, Huang H, Du Q, Geller DA and Cheng B: Notch and Wnt/β-catenin
signaling pathway play important roles in activating liver cancer
stem cells. Oncotarget. 7:5754–5768. 2016.PubMed/NCBI
|
|
13
|
Pandita A, Aldape KD, Zadeh G, Guha A and
James CD: Contrasting in vivo and in vitro fates of glioblastoma
cell subpopulations with amplified EGFR. Genes Chromosomes Cancer.
39:29–36. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vescovi AL, Galli R and Reynolds BA: Brain
tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasai K, Romer JT, Lee Y, Finkelstein D,
Fuller C, McKinnon PJ and Curran T: Shh pathway activity is
down-regulated in cultured medulloblastoma cells: Implications for
preclinical studies. Cancer Res. 66:4215–4222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Witt Hamer PC, VanTilborg AA, Eijk PP,
Sminia P, Troost D, Van Noorden CJ, Ylstra B and Leenstra S: The
genomic profile of human malignant glioma is altered early in
primary cell culture and preserved in spheroids. Oncogene.
27:2091–2096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clement V, Sanchez P, de Tribolet N,
Radovanovic I and Ruiz i Altaba A: HEDGEHOG-GLI1 signaling
regulates human glioma growth, cancer stem cell self-renewal, and
tumorigenicity. Curr Biol. 17:165–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Daniel VC, Marchionni L, Hierman JS,
Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M,
Peacock CD and Watkins DN: A primary xenograft model of small-cell
lung cancer reveals irreversible changes in gene expression imposed
by culture in vitro. Cancer Res. 69:3364–3373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tentler JJ, Tan AC, Weekes CD, Jimeno A,
Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG:
Patient-derived tumour xenografts as models for oncology drug
development. Nat Rev Clin Oncol. 9:338–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bousquet G and Janin A: Patient-derived
xenograft: An adjuvant technology for the treatment of metastatic
disease. Pathobiology. 83:170–176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fichtner I, Slisow W, Gill J, Becker M,
Elbe B, Hillebrand T and Bibby M: Anticancer drug response and
expression of molecular markers in early-passage xenotransplanted
colon carcinomas. Eur J Cancer. 40:298–307. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guenot D, Guérin E, Aguillon-Romain S,
Pencreach E, Schneider A, Neuville A, Chenard MP, Duluc I, Du
Manoir S, Brigand C, et al: Primary tumour genetic alterations and
intra-tumoral heterogeneity are maintained in xenografts of human
colon cancers showing chromosome instability. J Pathol.
208:643–652. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dangles-Marie V, Pocard M, Richon S,
Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N,
Validire P, et al: Establishment of human colon cancer cell lines
from fresh tumors versus xenografts: Comparison of success rate and
cell line features. Cancer Res. 67:398–407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Linnebacher M, Maletzki C, Ostwald C,
Klier U, Krohn M, Klar E and Prall F: Cryopreservation of human
colorectal carcinomas prior to xenografting. BMC Cancer.
10:3622010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Swaika A, Crozier JA and Joseph RW:
Vemurafenib: An evidence-based review of its clinical utility in
the treatment of metastatic melanoma. Drug Des Devel Ther.
8:775–787. 2014.PubMed/NCBI
|
|
26
|
Lasota J, Felisiak-Golabek A, Aly FZ, Wang
ZF, Thompson LD and Miettinen M: Nuclear expression and
gain-of-function β-catenin mutation in glomangiopericytoma
(sinonasal-type hemangiopericytoma): Insight into pathogenesis and
a diagnostic marker. Mod Pathol. 28:715–720. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for
response to panitumumab or cetuximab in metastatic colorectal
cancer. J Clin Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mori Y, Nagasaka T, Mishima H, Umeda Y,
Inada R, Kishimoto H, Goel A and Fujiwara T: The rare BRAF
VK600-601E mutation as a possible indicator of poor prognosis in
rectal carcinoma-a report of a case. BMC Med Genet. 16:12015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taieb J, Zaanan A, Le Malicot K, Julié C,
Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, et
al: Prognostic effect of BRAF and KRAS mutations in patients with
stage III colon cancer treated with leucovorin, fluorouracil, and
oxaliplatin with or without cetuximab: A post hoc analysis of the
PETACC-8 trial. JAMA Oncol. 14:1–11. 2016.
|
|
30
|
Jang GB, Kim JY, Cho SD, Park KS, Jung JY,
Lee HY, Hong IS and Nam JS: Blockade of Wnt/β-catenin signaling
suppresses breast cancer metastasis by inhibiting CSC-like
phenotype. Sci Rep. 5:124652015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barghout SH, Zepeda N, Xu Z, Steed H, Lee
CH and Fu Y: Elevated β-catenin activity contributes to carboplatin
resistance in A2780cp ovarian cancer cells. Biochem Biophys Res
Commun. 468:173–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wangpu X, Yang X, Zhao J, Lu J, Guan S, Lu
J, Kovacevic Z, Liu W, Mi L, Jin R, et al: The metastasis
suppressor, NDRG1, inhibits ‘stemness’ of colorectal cancer via
down-regulation of nuclear β-catenin and CD44. Oncotarget.
6:33893–33911. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Togashi Y, Hayashi H, Terashima M, de
Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K and Nishio K:
Inhibition of β-Catenin enhances the anticancer effect of
irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer
with a T790M mutation. J Thorac Oncol. 10:93–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang T, Zhang L, Fan S, Zhang M, Fu H,
Liu Y, Yin X, Chen H, Xie L, Zhang J, et al: Patient-derived
gastric carcinoma xenograft mouse models faithfully represent human
tumor molecular diversity. PLoS One. 10:e01344932015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin K, Li G, Cui B, Zhang J, Lan H, Han N,
Xie B, Cao F, He K, Wang H, et al: Assessment of a novel VEGF
targeted agent using patient-derived tumor tissue xenograft models
of colon carcinoma with lymphatic and hepatic metastases. PLoS One.
6:e283842011. View Article : Google Scholar : PubMed/NCBI
|
